Aldactone, which was frequently sold out, is resupplied

Supply of Rilutek will also normalize next month

Long-term out-of-stock imported drugs are expected to normalize

Pfizer Korea's diuretic drug Aldactone, which was often sold out, is scheduled to resume supply.

 

According to the distribution industry on the 27th, the supply of Aldactone (Spironolactone) 25mg is expected to resume from the 29th.

 

It was earlier than the April 8th, the resupply date originally expected by the company.

 

Aldactone is often sold out due to continued supply disruption.

 

Last year, there were five reports of production, import, and supply interruptions and shortages to the MFDS.

 

In December of last year, Pfizer expected to resume supply around February, but it was postponed for another two months.

 

This is because it has not been able to resolve the supply and demand of drug substance.

 

Aldactone was available from April.

 

Pfizer Korea said, "We apologize for the inconvenience caused by the sold-out of Aldactone, and we will do our best to stabilize supply." Sanofi Aventis' amyotrophic lateral sclerosis drug Rilutek, which has been out of stock for nearly two years, is also scheduled to be supplied at the end of April.

 

Sanofi Aventis explained, "We expect Rilutek to resume supply from the fourth week of April.

 

Based on the shipping date to the wholesaler, there may be 1-2 days difference by region.

 

There are no product codes, insurance, and benefit related changes," Sanofi explained.

 

Rilutek has not resumed supply since it temporarily sold out in October 2019.

 

This is due to a shortage of main ingredient raw materials in overseas manufacturers.

 

It was expected to resume in February 2020, but the company delayed the schedule until January this year.

 

Finally, supply started at the end of April.

 

Sanofi Aventis said, "We apologize once again for any inconvenience caused by supply instability.

 

We will do our best to supply the product smoothly with patient health as our top priority."